Claims
- 1. A method of topical treatment of an inflammatory condition of the skin comprising applying to the affected area a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase and is a pyrazolon derivative, and, currently therewith, a topically active anti-inflammatory corticosteroid, each of said prostaglandin synthetase inhibitor and said corticosteroid being applied in a pharmaceutically acceptable topical vehicle, the amounts of said anti-inflammatory drugs being sufficient in combination to combat said inflammatory condition.
- 2. The method of claim 1 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
- 3. The method of claim 2 wherein said corticosteroid is triamcinolone acetonide.
- 4. The method of claim 1 wherein said pyrazolon is phenylbutazone.
- 5. The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
- 6. The method of claim 1 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
- 7. The method of claim 5 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said topically active corticosteroid comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
- 8. The method of claim 5 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said non-steroidal inhibitor of prostaglandin synthetase comprising from about 0.5% to 10% by weight of suprofen.
- 9. A composition for the topical treatment of an inflammatory condition of the skin comprising a pharmaceutically acceptable topical vehicle containing a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase and is a pyrazolon derivative, and a topically active anti-inflammatory corticosteroid, the amounts of said anti-inflammatory drugs being sufficient, in combination, to combat said inflammatory condition.
- 10. The composition of claim 9 wherein said corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone 21-acetate, hydrocortisone 21-butyrate, desonide, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide and betamethasone-17-valerate.
- 11. The composition of claim 10 wherein said corticosteroid is triamcinolone acetonide.
- 12. The composition of claim 9 wherein said pyrazolon is phenylbutazone.
- 13. The composition of claim 9 wherein said topical vehicle comprises a mixture of propylene glycol and ethanol.
- 14. The composition of claim 9 wherein said topical vehicle comprises a mixture of propylene glycol and dimethylsulfoxide.
- 15. The composition of claim 13 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition further comprising from about 0.01% to about 0.5% by weight of triamcinolone acetonide.
- 16. The composition of claim 13 wherein said vehicle comprises approximately equal amounts by weight of said propylene glycol and said ethanol, said composition further comprising from about 0.5% to 10% by weight of suprofen.
- 17. The composition of claim 15 wherein said concentration is from about 0.05% to about 0.1%.
- 18. The composition of claim 16 wherein said concentration is from about 2% to about 5%.
- 19. A method of treating inflammatory conditions of the skin which comprises topically applying to the affected area the composition of claim 9.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a division, of application Ser. No. 788,453, filed Apr. 20, 1977, now U.S. Pat. No. 4,185,100 which is a continuation-in-part of our copending application Ser. No. 685,942, filed Many 13, 1976.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3479396 |
Buu-Hoi et al. |
Nov 1969 |
|
Non-Patent Literature Citations (3)
Entry |
Floman et al., Investigative Ophtholmology & Visual Science, vol. 16, No. 1, pp. 69-73, (1977). |
Lisciani et al., Japan J. Pharmacol, 25, pp. 101-107, (1975). |
Merck Index, 9th Ed., (1976), pp. 946-947. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
788453 |
Apr 1977 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
685942 |
May 1976 |
|